Lesions manifesting dermoscopic structures including granularity, angulated lines or certain dermoscopic patterns were most frequent characteristics of melanomas on nonfacial chronically sun-damaged skin, according to study results.
MRV Research
Dabrafenib plus trametinib improves health-related quality of life in metastatic melanoma
The addition of trametinib to dabrafenib improved health-related quality of life and reduced pain in patients with BRAF V600-mutated metastatic melanoma, according to results of a randomized phase 3 study.
Adjuvant ipilimumab improves survival after high-risk lymph node and melanoma resection
Results of an EORTC trial show that adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but this treatment is also associated with a high rate of immune-related adverse events.
Researchers Discover a Promising New Drug Target for Melanoma Treatment
A team of researchers from The University of North Carolina at Chapel Hill have recently reported the discovery of a new drug target for melanoma treatment. The study was published in the journal Clinical Cancer Research and is entitled “IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.”